Skip to main content

Table 4 Absorbed radiation doses and CSF/blood ratios

From: Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

 

Ratios

T test

Dose 1 Sampling (n = 33)

CSF (mGy/mCi)

1.01 (0.46–4.6)

 

Blood (mGy/mCi)

0.04 (0.01–0.24)

 

CSF/blood ratio

24 (3–767)

 

Dose 1 Scans (n = 23)

Brain(mGy/mCi)

1.16 (0.2–3.75)

 

CSF (mGy/mCi)

1.04 (0.25–2.84)

 

Dose 2 Sampling

 < 2220 MBq (n = 20) CSF

0.89 (0.34–2.18)

0.09*

 > 2220 MBq (n = 13)

1.37 (0.76–3.98)

 

 < 2220 MBq (n = 20) CSF/blood ratio

38.2 (4.8–59.3)

0.02*

 > 2220 MBq (n = 13)

50.7 (14.9–314.2)

 
 

Absorbed radiation dose (rads)

 

Cumulative dose for all administrations

CSF

1672 (336.2–8966)

 

Blood

82 (15–236.9)

 
  1. CSF cerebrospinal fluid
  2. *t test comparing patients with absorbed dose of < 2220 rads vs > 2220 rads